206000-71-7

Upstream product

• 206000-80-8 N-[(3RS)-5-acetoxymethyl-1-(3-azabicyclo[3.2.2]nonan-3-yl)carbonylmethyl-2,3-dihydro-9-methyl-1H-1,4-benzodiazepin-2-one-3-yl]-N'-(3-methylphenyl)urea 
• 205992-29-6 N-[(3RS)-1-(3-azabicyclo[3.2.2]nonan-3-yl)carbonylmethyl-2,3-dihydro-5,9-dimethyl-1H-1,4-benzodiazepin-2-one-4-oxido-3-yl]-N'-(3-methylphenyl)urea 
• 206001-28-7 FR 196979 
• 205992-19-4 (3RS)-1-(3-azabicyclo[3.2.2]nonan-3-yl)carboxymethyl-3-benzyloxycarbonylamino-2,3-dihydro-5,9-dimethyl-1H-1,4-benzodiazepin-2-one 
• 205992-02-5 (3RS)-3-benzyloxycarbonylamino-2,3-dihydro-5,9-dimethyl-1-ethoxy-carbonylmethyl-1H-1,4-benzodiazepin-2-one 
• 205992-20-7 (3RS)-3-amino-1-(3-azabicyclo[3.2.2]nonan-3-yl)carboxymethyl-2,3-dihydro-5,9-dimethyl-1H-1,4-benzodiazepin-2-one 
• 205992-15-0 (3RS)-3-benzyloxycarbonylamino-1-carboxymethyl-2,3-dihydro-5,9-dimethyl-1H-1,4-benzodiazepin-2-one 
• 205993-40-4 (3RS)-3-benzyloxycarbonylamino-2,3-dihydro-5,9-dimethyl-1H-1,4-benzodiazepin-2-one 
• 95-53-4 o-toluidine 
• 53657-94-6 2-methyl-6-acetylaniline 

Relevant academic research and scientific papers

Dual CCK-A and CCK-B receptor antagonists (II). Preparation and structure activity relationships of 5-alkyl-9-methyl-1,4-benzodiazepines and discovery of FR208419

In our continuing research for dual CCK-A and -B antagonists, according to our hypothesis that dual CCKA and -B antagonists should be more efficacious than selective CCK-A antagonists for the treatment of pancreatitis, we have prepared various 5-alkyl-9-m